Moderna Inc. Sees Stock Surge with 2025 Revenue Outlook of $1.9 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Should l Buy MRNA?
Source: Benzinga
- Momentum Score Surge: Moderna's momentum score skyrocketed from 22.5 to 74.61 in just one week, indicating a significant shift in investor sentiment and reflecting increased confidence in the company's future performance.
- Stock Price Recovery: The stock has risen 76% since its November 2025 lows, climbing 31.7% in the past month, showcasing a robust market rebound that further boosts investor optimism.
- Revenue Outlook Upgrade: The company has raised its 2025 revenue forecast to $1.9 billion, approximately $100 million above the midpoint provided during the third-quarter earnings call, indicating a strong recovery momentum in its business.
- Cost Control Improvement: Moderna has lowered its GAAP operating expense forecast by about $200 million and expects a year-end cash balance of $8.1 billion, further enhancing investor confidence in the stock.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 50.110
Low
17.00
Averages
32.47
High
63.00
Current: 50.110
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna and Target Stocks Show Recovery
- Moderna Stock Surge: Since the beginning of the year, Moderna's stock has surged nearly 70%, driven by the launch of new vaccine products and a focus on seasonal vaccines, with expectations of up to 10% revenue growth this year, indicating a recovery that is attracting investor interest.
- Vaccine Revenue Support: After generating over $18 billion in vaccine revenue in 2022, Moderna is reshaping its revenue structure by introducing new COVID-19 and RSV vaccines, with seasonal vaccines expected to drive the development of other programs.
- Target's Strategic Transformation: Target's stock has risen over 20% since the start of the year, thanks to a $200 million investment plan by new CEO Michael Fiddelke aimed at improving product displays, refreshing the product assortment, and enhancing employee training to boost customer experience and sales growth.
- Competitive Advantage Enhancement: Despite pressure from competitors like Walmart, Target's lower forward P/E ratio of 14x compared to peers indicates greater growth potential, suggesting that its recovery story in the retail market is ongoing and attracting investor attention.
See More
Investors Shift Focus to Healthcare and Retail Stocks
- Market Shift: In an uncertain market, investors are turning to healthcare and retail stocks, perceived as 'safer' investments due to their potential for revenue stability, reflecting concerns over slowing economic growth.
- Moderna's Recovery: Moderna generated over $18 billion from its COVID-19 vaccine during the pandemic's early days, but its stock plummeted 90% as demand waned; however, investors are now returning, anticipating up to 10% revenue growth in 2023 as it focuses on seasonal vaccines, oncology, and rare diseases.
- Target's Transformation: Target benefited from digital initiatives during the pandemic but faced challenges afterward; new CEO Michael Fiddelke has launched a multi-year $2 billion investment plan to enhance product displays and employee training, resulting in a stock price increase of over 20% since the start of the year.
- Investment Opportunities: With increasing market interest in healthcare and retail stocks, the recovery narratives of Moderna and Target are attracting investors, particularly as Target's price-to-earnings ratio stands at just 14 times, significantly lower than its competitors, indicating substantial growth potential ahead.
See More
Sysco and McCormick Announce Major Acquisitions
- Sysco Acquisition Update: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across 700,000 restaurants, although it faces potential antitrust scrutiny that could complicate the deal.
- McCormick and Unilever Merger: McCormick announced a $44 billion merger with Unilever's food division, despite being valued at only $14 billion itself, indicating a strategic move to leverage scale and synergies, though past similar deals have often failed to deliver expected value.
- M&A Activity in Food Sector: The recent surge in mergers within the food industry highlights a market trend towards consolidation and economies of scale, yet historical data suggests that many large consumer brand mergers have not yielded positive outcomes, prompting investors to proceed with caution.
- Eli Lilly's Centessa Acquisition: Eli Lilly is acquiring Centessa Pharmaceuticals for $7.8 billion, focusing on expediting the market entry of a promising narcolepsy treatment, despite Centessa lacking commercial products, with success hinging on upcoming clinical trial results.
See More
Surge in M&A Activity in the Food Sector
- Sysco Acquisition Move: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across its network of 700,000 restaurants, thereby solidifying its leadership position in the U.S. food service distribution market.
- McCormick and Unilever Merger: McCormick announced a merger with Unilever's food division valued at $44 billion, despite McCormick's market cap of only $14 billion, indicating a strategy to leverage scale and resource integration for improved profitability, though it faces integration risks.
- Market Reactions and Risks: Analysts express caution regarding both Sysco and McCormick's transactions, particularly with Sysco taking on $21 billion in new debt, which could impact its financial stability, while the success of McCormick's merger strategy remains to be seen.
- Eli Lilly Acquires Centessa: Eli Lilly announced the acquisition of Centessa Pharmaceuticals for $7.8 billion, focusing on rare disease treatments; if FDA approval is secured, it could tap into a $5 billion market, reflecting strong demand and investment willingness in the pharmaceutical sector.
See More
Moderna's Stock Soars 72% in Q1, Leading Healthcare Sector
- Shift in Investor Sentiment: Moderna's stock surged 72% in Q1, making it the best-performing healthcare stock in the S&P 500, reflecting a renewed investor confidence in its growth potential after a period of declining stock performance due to reduced vaccine demand.
- Diversification Strategy: The company is transitioning from a coronavirus vaccine manufacturer to a multi-faceted biotech firm, with plans to launch a flu vaccine alongside existing COVID-19 and RSV vaccines, which are expected to fund its oncology and rare disease initiatives.
- Revenue Growth Expectations: Moderna anticipates that seasonal vaccines will drive up to 10% revenue growth this year, and by cutting costs by 30% since 2024, it achieved over $2 billion in savings last year, enhancing its financial stability.
- Clinical Trial Progress: The ongoing collaboration with Merck on the mRNA-4157 project includes eight phase 2 and phase 3 trials, and successful results could significantly boost its competitive position in the oncology market, further solidifying its market presence.
See More
Moderna's Stock Soars 72% in Q1, Leading Healthcare Sector
- Outstanding Stock Performance: Moderna's stock surged 72% in Q1, making it the best performer among healthcare companies in the S&P 500, indicating a significant shift in investor sentiment amidst a broader market aversion to AI and growth stocks.
- Revenue Growth Expectations: The company anticipates seasonal vaccines could deliver up to 10% revenue growth, with its new vaccine pipeline, including flu and norovirus vaccines, expected to fund its oncology and rare disease programs, thereby enhancing its market competitiveness.
- Significant Cost Control: Moderna has reduced costs by 30% since 2024, achieving over $2 billion in savings last year, which provides robust financial support for future R&D and market expansion efforts.
- Notable Oncology Progress: Moderna is conducting eight phase 2 and phase 3 clinical trials in collaboration with Merck, particularly for melanoma, with phase 3 data expected this year, which could further solidify its position in the oncology market.
See More
Moderna and Target Stocks Show Recovery
- Moderna Stock Surge: Since the beginning of the year, Moderna's stock has surged nearly 70%, driven by the launch of new vaccine products and a focus on seasonal vaccines, with expectations of up to 10% revenue growth this year, indicating a recovery that is attracting investor interest.
- Vaccine Revenue Support: After generating over $18 billion in vaccine revenue in 2022, Moderna is reshaping its revenue structure by introducing new COVID-19 and RSV vaccines, with seasonal vaccines expected to drive the development of other programs.
- Target's Strategic Transformation: Target's stock has risen over 20% since the start of the year, thanks to a $200 million investment plan by new CEO Michael Fiddelke aimed at improving product displays, refreshing the product assortment, and enhancing employee training to boost customer experience and sales growth.
- Competitive Advantage Enhancement: Despite pressure from competitors like Walmart, Target's lower forward P/E ratio of 14x compared to peers indicates greater growth potential, suggesting that its recovery story in the retail market is ongoing and attracting investor attention.
See More
Investors Shift Focus to Healthcare and Retail Stocks
- Market Shift: In an uncertain market, investors are turning to healthcare and retail stocks, perceived as 'safer' investments due to their potential for revenue stability, reflecting concerns over slowing economic growth.
- Moderna's Recovery: Moderna generated over $18 billion from its COVID-19 vaccine during the pandemic's early days, but its stock plummeted 90% as demand waned; however, investors are now returning, anticipating up to 10% revenue growth in 2023 as it focuses on seasonal vaccines, oncology, and rare diseases.
- Target's Transformation: Target benefited from digital initiatives during the pandemic but faced challenges afterward; new CEO Michael Fiddelke has launched a multi-year $2 billion investment plan to enhance product displays and employee training, resulting in a stock price increase of over 20% since the start of the year.
- Investment Opportunities: With increasing market interest in healthcare and retail stocks, the recovery narratives of Moderna and Target are attracting investors, particularly as Target's price-to-earnings ratio stands at just 14 times, significantly lower than its competitors, indicating substantial growth potential ahead.
See More
Sysco and McCormick Announce Major Acquisitions
- Sysco Acquisition Update: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across 700,000 restaurants, although it faces potential antitrust scrutiny that could complicate the deal.
- McCormick and Unilever Merger: McCormick announced a $44 billion merger with Unilever's food division, despite being valued at only $14 billion itself, indicating a strategic move to leverage scale and synergies, though past similar deals have often failed to deliver expected value.
- M&A Activity in Food Sector: The recent surge in mergers within the food industry highlights a market trend towards consolidation and economies of scale, yet historical data suggests that many large consumer brand mergers have not yielded positive outcomes, prompting investors to proceed with caution.
- Eli Lilly's Centessa Acquisition: Eli Lilly is acquiring Centessa Pharmaceuticals for $7.8 billion, focusing on expediting the market entry of a promising narcolepsy treatment, despite Centessa lacking commercial products, with success hinging on upcoming clinical trial results.
See More
Surge in M&A Activity in the Food Sector
- Sysco Acquisition Move: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across its network of 700,000 restaurants, thereby solidifying its leadership position in the U.S. food service distribution market.
- McCormick and Unilever Merger: McCormick announced a merger with Unilever's food division valued at $44 billion, despite McCormick's market cap of only $14 billion, indicating a strategy to leverage scale and resource integration for improved profitability, though it faces integration risks.
- Market Reactions and Risks: Analysts express caution regarding both Sysco and McCormick's transactions, particularly with Sysco taking on $21 billion in new debt, which could impact its financial stability, while the success of McCormick's merger strategy remains to be seen.
- Eli Lilly Acquires Centessa: Eli Lilly announced the acquisition of Centessa Pharmaceuticals for $7.8 billion, focusing on rare disease treatments; if FDA approval is secured, it could tap into a $5 billion market, reflecting strong demand and investment willingness in the pharmaceutical sector.
See More
Moderna's Stock Soars 72% in Q1, Leading Healthcare Sector
- Shift in Investor Sentiment: Moderna's stock surged 72% in Q1, making it the best-performing healthcare stock in the S&P 500, reflecting a renewed investor confidence in its growth potential after a period of declining stock performance due to reduced vaccine demand.
- Diversification Strategy: The company is transitioning from a coronavirus vaccine manufacturer to a multi-faceted biotech firm, with plans to launch a flu vaccine alongside existing COVID-19 and RSV vaccines, which are expected to fund its oncology and rare disease initiatives.
- Revenue Growth Expectations: Moderna anticipates that seasonal vaccines will drive up to 10% revenue growth this year, and by cutting costs by 30% since 2024, it achieved over $2 billion in savings last year, enhancing its financial stability.
- Clinical Trial Progress: The ongoing collaboration with Merck on the mRNA-4157 project includes eight phase 2 and phase 3 trials, and successful results could significantly boost its competitive position in the oncology market, further solidifying its market presence.
See More
Moderna's Stock Soars 72% in Q1, Leading Healthcare Sector
- Outstanding Stock Performance: Moderna's stock surged 72% in Q1, making it the best performer among healthcare companies in the S&P 500, indicating a significant shift in investor sentiment amidst a broader market aversion to AI and growth stocks.
- Revenue Growth Expectations: The company anticipates seasonal vaccines could deliver up to 10% revenue growth, with its new vaccine pipeline, including flu and norovirus vaccines, expected to fund its oncology and rare disease programs, thereby enhancing its market competitiveness.
- Significant Cost Control: Moderna has reduced costs by 30% since 2024, achieving over $2 billion in savings last year, which provides robust financial support for future R&D and market expansion efforts.
- Notable Oncology Progress: Moderna is conducting eight phase 2 and phase 3 clinical trials in collaboration with Merck, particularly for melanoma, with phase 3 data expected this year, which could further solidify its position in the oncology market.
See More
